Jeffery Gardner - CAMP4 THERAPEUTICS Independent Director
| CAMP Stock | USD 5.26 0.26 5.20% |
Director
Mr. Jeffery R. Gardner is an independent Director of the Company. Since 2015 he has served as the President and CEO of Brinks Home Security. Mr. Gardner also serves as a director of Ascent Capital Group, Inc., the publicly held parent company of Brinks Home Security, and Qorvo, Inc., the holding company under which RF Micro Devices, Inc. and TriQuint Semiconductor, Inc. were combined in 2014. Prior to that, Mr. Gardner served on the board of RF Micro Devices since 2004. In addition, from 2005 until 2015, Mr. Gardner was a director of Windstream Corporation, a leading provider of advanced network communications and technology solutions, including cloud computing and managed services. Mr. Gardner also served as the President and CEO of Windstream from 2005 until 2014. Before joining Windstream, Mr. Gardner served as Executive Vice President and CFO of Alltel Corporationration Earlier, Mr. Gardner held a variety of senior management positions at 360 Communications, which merged with Alltel in 1998 since 2015.
| Age | 64 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | One Kendall Square, Cambridge, MA, United States, 02139 |
| Phone | (617) 651-8867 |
| Web | https://www.camp4tx.com |
Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Didier Hirsch | Knowles Cor | 69 | |
| Christopher Genualdi | NETGEAR | N/A | |
| Hermann Eul | Knowles Cor | 62 | |
| Ye Li | Knowles Cor | 53 | |
| Keith Barnes | Knowles Cor | 69 | |
| Cheryl Shavers | Knowles Cor | 67 | |
| Ronald Jankov | Knowles Cor | 61 | |
| CFA CMA | Telesat Corp | N/A | |
CAMP4 THERAPEUTICS Leadership Team
Elected by the shareholders, the CAMP4 THERAPEUTICS's board of directors comprises two types of representatives: CAMP4 THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CAMP4. The board's role is to monitor CAMP4 THERAPEUTICS's management team and ensure that shareholders' interests are well served. CAMP4 THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CAMP4 THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Gold, Chief Officer | ||
| John Partain, Interim Experience | ||
| Erik Schulz, Interim Officer | ||
| Joshua MandelBrehm, President CEO | ||
| Christian Horne, Interim Sales | ||
| Brett Jackson, Senior Logistics | ||
| Mark Gaydos, Chief Officer | ||
| Michael Zachan, Senior Unit | ||
| Nathan Lowstuter, Senior Officer | ||
| Xiaolian Zhang, Senior Analysis | ||
| Caleb Moore, Chief Operations | ||
| Maurizio Iperti, President Automotive | ||
| Richard Young, Founder Director | ||
| David Bumcrot, Chief Research | ||
| Daniel Tardiff, VP Discovery | ||
| Monica Berkel, Senior President | ||
| Michelle Gates, Senior Officer | ||
| Chris Adams, President CEO | ||
| Leonard MD, Founder | ||
| Jeffery Gardner, Independent Director | ||
| Richard Scott, Chief VP | ||
| Scott Tripp, VP Operations | ||
| MD MBA, Chief Officer | ||
| Richard Vitelle, CFO, Executive VP, Corporate Secretary and Treasurer | ||
| Anand Rau, VP CTO | ||
| Jikun Kim, Senior CFO | ||
| Satya Kuchimanchi, Senior Operations |
CAMP4 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CAMP4 THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 109.74 M | ||||
| Shares Outstanding | 20.16 M | ||||
| Shares Owned By Insiders | 35.40 % | ||||
| Shares Owned By Institutions | 56.95 % | ||||
| Number Of Shares Shorted | 359.72 K | ||||
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| Gross Profit | (37.93 M) | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) |
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.